Science & Policy: The Future of Cancer Care 

The American Cancer Society recently shared a bleak figure – for the first time, new cases of cancer in the United States are expected to cross the 2-million mark.
 
While advancements in care have led to a steady decline in cancer deaths over the last 30 years, rising cases for many common cancers put that progress at risk. More than 313,000 new breast cancer cases are projected for 2024.  
 
How can the federal government, healthcare providers, patients, and other stakeholders work together to promote innovations for cancer prevention and treatments? How should we address inequities when it comes to screening, diagnostics, and cancer care? And how can we reverse the trend of rising cancer incidence in the United States?  

Join The Hill’s cancer summit where administration officials, lawmakers, patient advocates, doctors, and scientists weigh in on how to accelerate critical research and equity with the goal of putting an end to cancer. 

LOCATION
Top of the Hill, 1 Constitution Ave NE, Washington, DC 20002, and streaming nationwide

DATE & TIME
Thursday, May 9
8:00 AM ET Registration & Networking
8:30 AM ET Programming begins
10:00 AM ET Programming concludes

Program Segments:

Bipartisan Perspective (in conversation with Bob Cusack, Editor in Chief, The Hill)

• Rep. John Joyce (R-PA), Co-Sponsor, ORPHAN Cures Act 
• Rep. Wiley Nickel (D-NC), Co-Sponsor, ORPHAN Cures Act

White House Cancer Update (in conversation with Bob Cusack, Editor in Chief, The Hill)

• Dr. Danielle Carnival, Deputy Assistant to the President, White House Cancer Moonshot; Deputy Director – Health Outcomes, White House Office of Science & Technology Policy

Panel Discussion: Mitigating Inequities in Cancer Care (in conversation with Bob Cusack, Editor in Chief, The Hill)

• Dr. Crystal Denlinger, CEO, National Comprehensive Cancer Network (NCCN)
• Pam Traxel, SVP – Alliance Development & Philanthropy, American Cancer Society Cancer Action Network
• Maimah Karmo, Founder & CEO, Tigerlily Foundation

Sponsor Perspective (in conversation with Kathleen Koch, Contributing Editor, The Hill)

• Mohit Manrao, SVP & Head – U.S. Oncology Business Unit, AstraZeneca

Industry Perspective (in conversation with Bob Cusack, Editor in Chief, The Hill)

• John Crowley, President & CEO, BIO

Have a question? Reach us on social media @TheHillEvents using #TheHillCancer

Sponsored by:

AstraZeneca is a science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. At AstraZeneca, we have a bold ambition to provide cures for cancer in every form. Working in partnership with all our stakeholders, we are harnessing the power of science and innovation to deliver life-changing medicines. By understanding the complexities of cancer, we hope to revolutionize oncology treatments and increase the potential to save the lives of people around the world. Learn more about our oncology work here.